
|Videos|July 15, 2021
Incorporating Esketamine into Practice for Treatment-Resistant Depression
Advertisement
Episodes in this series

Requirements that healthcare clinics must satisfy to become a certified treatment center permitted to administer intranasal esketamine to patients with treatment-resistant depression.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults
2
Quiet Comfort: New Details on COMP360 Psilocybin Administration Sessions for the Treatment of PTSD
3
Preventing Alzheimer Disease After Brain Injury: Targeting TNF With XPro1595
4
Phase 2 Topline Results From ZEPHYR Trial: ML-007C-MA for the Treatment of Schizophrenia
5






